36
Views
3
CrossRef citations to date
0
Altmetric
Original article

Changes in the plasma levels of protein C system parameters in pregnancy

, &
Pages 481-488 | Received 05 May 2003, Accepted 05 Sep 2003, Published online: 08 Jul 2009

REFERENCES

  • de Boer K, ten Cate JW, Sturk A, Borm JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95–100.
  • Stirling Y, Woolf I, North WRS, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176–82.
  • Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80: 132.
  • Halligan A, Bonnar J, Sheppard B. Haemostatic, fibrinolytic and endothelial variables in normal preg-nancies and preeclampsia. Br J Obstet Gynaecol 1994; 101: 488.
  • Cadroy Y, Boneu B. Coagulation in normal pregnancy and gestosis. Diagnos Labor 1994; 44: 86 — 94.
  • Walker ID. Thrombophilia in pregnancy. J Clin Pathol 2000; 53: 573–80.
  • Rosen SB, Sturk A. Activated protein C resistance—a major risk factor for thrombosis. Eur J Clin Chem Biochem 1997; 35: 501–16.
  • Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004–8.
  • Dahlback B. Physiological anticoagulation: resis-tance to activated protein C and venous thrombo-embolism. J Clin Invest 1994; 94: 923–7.
  • Bertina RM, Koeleman RPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7.
  • Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated pro-tein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449— 53.
  • Koster T, Rosendaal FR, Briet E, van der Meer FJM. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631–5.
  • Lockwood CJ. Inherited thrombophilias in preg-nancy patients: detection and treatment paradigm. Obstet Gynecol 2002; 99: 333–41.
  • Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725–7.
  • Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210–3.
  • Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998; 244: 27–32.
  • Clark P, Sattar N, Walker ID, Greer IA. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy asso-ciated activated protein C resistance. Thromb Haemost 2001; 85: 30–5.
  • Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551 — 4.
  • Rai R, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489–90.
  • Ridker PM, Miletic JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000–3.
  • Paternoster DM, Stella A, Simioni P, Girolami A, Snijders D. Activated protein C resistance in normal and pre-eclamptic pregnancies. Gynecol Obstet Invest 2002; 54: 145–9.
  • Grandone E, Margaglione M, Colaizzo D, Daddedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Diminno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822–4.
  • Gemmati D, Serino ML, Scapoli GL. A modified functional global test to measure protein C, protein S activities and the activated protein C resistance phenotype. Thromb Res 1998; 92: 141–8.
  • Dati F, Hafner G, Erbes H, Kraus M, Niemann F, Noah M, Wagner C. Pro CgGlobal: The first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719–23.
  • Bauer EL. Statistical methods for chemists. UK: Academic Press; 1971. p. 71–93.
  • Ignjatovié S. Biohemijski parametri akutnog pank-reatitisa: analitiCka i kliniCka vrednost. Doktorska disertacija. Farmaceutski fakultet. Univerzitet u Beogradu, 1997.
  • Zveig MH, Campbell G. Receiver operating characteristic (ROC) plots: a fundamental evalua-tion tool in clinical medicine. Clin Chem 1993; 39/4: 561–77.
  • Clark P, Brennand J, Conkie JA, McCall, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998 Jun; 79: 1166–70.
  • Mathonnet F, de Mazancourt P, Bastenaire B, Benattar N. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996; 92: 244–6.
  • Manning RM, Letsky EA, Nelson-Piercy C, Peek MJ, de Swiet M. Activated protein C resistance in normal pregnancy. Br J Haematol 1997; 104: 1084— 6.
  • Shu H, Wramsby M, Bokarewa M, Blomback M, Bremme K. Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy. J Thromb Thrombolysis 2000; 9: 277–81.
  • Benedetto C, Marozio L, Tavella AM, Maula V, Carmignani D, Curti. Response to activated protein C decreases throughout pregnancy. Acta Obstet Gynecol Scand 2002; 81: 1028–32.
  • Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285–93.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.